



(51) International Patent Classification:

A61K 31/53 (2006.01) *A61P 9/12* (2006.01)
A61P 3/04 (2006.01)

(21) International Application Number:

PCT/US2014/042628

(22) International Filing Date:

17 June 2014 (17.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/836,200 18 June 2013 (18.06.2013) US

(71) Applicant: ALBERT EINSTEIN COLLEGE OF
MEDICINE OF YESHIVA UNIVERSITY [US/US];
1300 Morris Park Avenue, Bronx, NY 10461 (US).

(72) Inventors: SCHUSTER, Victor, L.; 275 West 96th Street,
Apt. 12-d, New York, NY 10025 (US). CHI, Yuling; 181
Harding Drive, New Rochelle, NY 10801 (US).

(74) Agents: ARNOLD, Craig, J. et al.; Amster, Rothstein &
Ebenstein Llp, 90 Park Avenue, New York, NY 10016
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION

(57) Abstract: Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.



TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 61/836,200, filed June 18, 2013, the contents of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

[0002] Various publications are referred to in parentheses throughout this application. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference in their entireties into the subject application to more fully describe the art to which the subject application pertains.

[0003] Prostaglandins (PGs) are synthesized from arachidonic acid by cyclooxygenases (COX1 and COX2) and corresponding synthases (Helliwell et al. 2004). PGs play an important role in physiology and clinical settings. Their biological effects include triggering inflammation, fever and pain (Blatteis and Schic, 1997; Bley et al., 1998; Vanegas and Schaible, 2001; Samad et al., 2002); induction of labor (Ulmann et al., 1992); modulation of renal hemodynamics and of water and solute reabsorption (Epstein, 1986; Wang et al., 1998; Yokoyama et al., 2002); arterial vasodilatation (Clyman et al., 1978; Coceani and Olley, 1988; Smith et al., 1994); stimulation of cell proliferation and angiogenesis (Ferrara et al, 1997; Tsujii et al, 1998; Young, 2004; Mann et al, 2006; Sheng et al, 2001; Shao et al, 2006); and mediating sensitization of sensory neurons (Southall and Vasko, 2000; Southall and Vasko, 2001; Seybold et al., 2003). PG analogues, such as latanoprost and unoprostone, have been used to treat glaucoma (Stjernschantz, 1995; Alm, 1998; Susanna et al., 2002; Stjernschantz, 2004). At the cellular level, PGs are involved in several major signaling pathways, including the mitogen-activated protein (MAP) kinase and protein kinase A pathways by upregulation of cAMP (Narumiya et al., 1999; Bos et al., 2004).

[0004] The magnitude of PG effects depends not only on their production but also their metabolism. The prostaglandin transporter (PGT) (Kanai et al., 1995; U.S. Patent No. 5,792,851) removes PGs from the extracellular compartment and thereby terminates their

-2-

interactions with receptors on cell membranes. PGT delivers PGs to cytoplasmic 15-OH PG dehydrogenase (Schuster, 2002; Nomura et al., 2004), resulting in oxidation and inactivation. Because PGT is highly expressed in the tissues and organs where PGs are synthesized (Bao et al., 2002), and because PGT regulates a broad and complex PG signaling system, inhibitors of PGT are important for manipulating signaling. Inhibition of PGT lowers blood pressure by vasodilation and natriuresis and inhibits platelet aggregation.

[0005] Known PGT blockers include inhibitors of the organic anion transporters (OATs), such as bromocresol green and bromosulphophthalein, and some COX2 inhibitors, such as indomethacin and ibuprofen (Bito and Salvador, 1976; Kanai et al., 1995). One of the main problems with these inhibitors is that they are not specific for PGT (Jacquemin et al., 1994; Sweet et al., 1997). Recently, specific PGT inhibitors have been developed (Chi et al., 2005; WO 2007/136638; US 2012/0238577).

[0006] Obesity is a world-wide epidemic associated with significant morbidity and mortality which costs billions of dollars per year (e.g., Carter et al., 2012; Holes-Lewis et al., 2013; Santo-Domingo et al. 2012). The need for more effective medications and treatments remains clear.


[0007] Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure, with an estimated incidence of 1–2 cases per 1 million persons in the general population (Patel et al., 2012). Despite advances in diagnosis and treatment, new therapeutic strategies are urgently required (Agarwal and Gomberg-Maitland, 2012; Yao, 2012).

[0008] The present invention addresses the need for treatments for pulmonary arterial hypertension and obesity, using inhibitors of PGT.

SUMMARY OF THE INVENTION

[0009] The invention provides methods of treating obesity and/or pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension, wherein formula (I) is:

-3-



(I), where the variables R1, R2, R3, R4 and W are defined herein below.

[00010] The invention also provides methods of treating a condition selected from the group consisting of obesity and pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a prostaglandin transporter inhibitor in an amount effective to treat obesity and/or pulmonary arterial hypertension.

[00011] The invention further provides pharmaceutical compositions for treating obesity and/or pulmonary arterial hypertension comprising a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier.

[00012] The invention also provides pharmaceutical compositions for treating obesity and/or pulmonary arterial hypertension comprising a prostaglandin transporter inhibitor in an amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

[00013] Figure 1A-1C. WT C57BL6 and PGT Knock-out (KO) mice were fed with chow diet (CD) or high fat diet (HFD) and treated with vehicle (0.4% DMSO + 0.4% cremophore) or 0.2 mM Compound 146 ("PV") in drinking water. Mice were housed individually and fed with CD or HFD, and water (with or without Compound 146) *ad libitum*. Body weight gain (A), food (B) and water (C) intake were recorded every other day. (n = 3-4).

[00014] Figure 2. Glucose tolerance test. WT C57BL6 and PGT KO mice were fed with CD or HFD and treated with vehicle (0.4% DMSO + 0.4% cremophore) or 0.2 mM Compound 146 ("PV") in drinking water for 67 days (n = 3-4).

[00015] Figure 3. Right ventricular systolic (RVSP; left) and mean (RVMP; right) pressures in the study subjects. Bars represent mean ± S.E. Asterisks represent significant difference from control groups (P<0.05) by ANOVA with Newman-Keuls Multiple Comparison Test. PV = Compound 146; Compound 146 low dose ("PVlow") = 15 mg/kg b.i.d.; Compound 146 high dose ("PVHigh") = 50 mg/kg, b.i.d.

-4-

[00016] Figure 4. Right ventricular pulse pressure (left) and heart rate (right) in the study subjects, obtained at sacrifice. Bars represent mean $\pm$ S.E. The asterisk represents significant difference between the MCT+Vehicle and all other groups ($P<0.05$) by ANOVA with Newman-Keuls Multiple Comparison Test. Hash mark indicates that MCT+Compound 146 were significantly reduced compared to MCT+Vehicle. PV = Compound 146; Compound 146 low dose ("PVlow") = 15 mg/kg b.i.d.; Compound 146 high dose ("PVHigh") = 50 mg/kg, b.i.d.

[00017] Figure 5. Right ventricular hypertrophy (RV/LVS, left) and contractility (max dP/dt, right) in the study subjects, obtained at sacrifice. Bars represent mean $\pm$ S.E. Three asterisks (***) represents significant difference between the MCT-Vehicle groups and all others by ANOVA with Newman-Keuls Multiple Comparison Test ($P<0.05$). Two asterisks denotes significant difference between MCT-Compound 146 high group and Saline-Vehicle controls ($P<0.01$). PV = Compound 146; Compound 146 low dose ("PVlow") = 15 mg/kg b.i.d.; Compound 146 high dose ("PVHigh") = 50 mg/kg, b.i.d.


[00018] Figure 6. Total lung weights in all treatment groups. MCT alone increased lung weights compared to all other groups. Asterisks (**) indicate significant difference from control and PV-02076 groups by ANOVA with Newman-Keuls Multiple Comparison Test ($P<0.01$). PV = Compound 146; Compound 146 low dose ("PVlow") = 15 mg/kg b.i.d.; Compound 146 high dose ("PVHigh") = 50 mg/kg, b.i.d.

[00019] Figure 7. Right lung lobe wet (left), dry (center) weights and the wet:dry ratio (right) data from all subjects. Two asterisks (**) indicate significant difference from control and PV-02076 groups by ANOVA with Newman-Keuls Multiple Comparison Test ($P<0.01$). Single asterisks (*) indicate significant different between MCT-PV-02076 groups and Saline-Vehicle. PV = Compound 146; Compound 146 low dose ("PVlow") = 15 mg/kg b.i.d.; Compound 146 high dose ("PVHigh") = 50 mg/kg, b.i.d.








DETAILED DESCRIPTION OF THE INVENTION

[00020] The invention provides a method of treating a condition selected from the group consisting of obesity and pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension, wherein formula (I) is:

-5-




wherein


W is O or NR₅;R₁ is H, -CH₃, -(CH₂)₂OH,R₃ is -(CH₂)₅CH₃, -(CH₂)₆CO₂H, -(CH₂)₆CO₂CH₃, -(CH₂)_dNHCO-Ph, -(CH₂)₆CONH-Ph,R₄ and R₅ are independently H or -CH₃;R₆ is O or NR₉;

-6-

R7 is H, -CH₃, -C(CH₃)₃, -CH₂OH, -(CH₂)₂OH, -(CH₂)₂O(CH₂)₂OH, -(CH₂CH₂O)₃CH₃,
 -(CH₂CH₂O)₂CH₂CO₂CH₃, -(CH₂)₅CH₃,




R8 is H, -OH, -CH₂OH, -CO₂H, -CO₂CH₂CH₃, -CO(CH₂)₆CH₃, -OCH₃, -NH₂,




R9 is H or -CH₃;

R10 is -CH₂NH₂, -CO₂H or -CO₂CH₃;

R11 is -SO₂-Ph, -CH₂-Ph, -CONH-Ph, -COCH₃,



R12 is -CH₃, $(\text{Cyclopentyl})-$, $(\text{Pyrrolyl})-$, $(\text{Furanyl})-$, $(\text{Thienyl})-$,



where X1, X2, X3, X4, X5, X6 and X7 are independently H, halogen, -OH, -CH₃, -CF₃,
 -OCH₃, -CO₂H, -CO₂CH₃, -CH₂CO₂H, -CH₂CO₂CH₃, phenyl or -O-Bn; and where a = 0-2; b
 = 1-6; c = 0-1; d = 4-7; and e = 0-1; or a pharmaceutically acceptable salt thereof.

-7-

[00021] As used herein in chemical structures, “Ph” stands for phenyl, “Bn” stands for benzyl ($-\text{CH}_2\text{Ph}$), “Bz” stands for benzoyl ($-(\text{C}=\text{O})\text{Ph}$), and “Me” stands for methyl ($-\text{CH}_3$). The point of attachment of the side group substitution to the main part of the compound is indicated by “().” The terms ortho, meta and para refer to the positions of substitutions in relation to the main part of the compound.


[00022] In preferred compounds, W is NR5. In preferred compounds, R6 is NR9.

[00023] In preferred compounds, at least one of R4, R5 and R9 is H, or all of R4, R5 and R9 are H. Preferably, at least R5 (out of R4, R5 and R9) is H.


[00024] In preferred compounds, one of X1 and X2 is H, and the other is halogen, $-\text{CF}_3$, $-\text{CH}_3$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{OCH}_3$ or phenyl. In preferred compounds, one of X3 and X4 is $-\text{OH}$, and the other is halogen, $-\text{CO}_2\text{H}$ or $-\text{CO}_2\text{CH}_3$. In preferred compounds, X7 is H, $-\text{CF}_3$ or $-\text{OCH}_3$.

[00025] In preferred compounds, one or both of X1 and X2 are located in ortho position, or one or both of X1 and X2 are located in meta position, or X1 is located in meta position and X2 is located in para position, or X1 is located in ortho position and X2 is located in para position. In preferred compounds, X3 is in meta position and X4 is in para position. In preferred compounds, X5 or X6 is in meta position, or X5 or X6 is in para position.


[00026] Preferred compounds have the structure:



-8-






or



; or a pharmaceutically acceptable salt



thereof.

[00027] In preferred compounds,




where X1, X2, X3, X4, X5 and X6 are independently H, halogen, -OH, -CH₃, -CF₃, -OCH₃, -CO₂H, -CO₂CH₃, -CH₂CO₂H or -CH₂CO₂CH₃; and where a = 1-2; and b = 1-5; or a pharmaceutically acceptable salt thereof.

[00028] In preferred compounds,




-9-



where X1 is H or halogen; where X4 is H, halogen or -CO₂H; and where X5 is H, halogen or -OCH₃; or a pharmaceutically acceptable salt thereof.

[00029] Preferred compounds have the structure:




or a pharmaceutically acceptable salt thereof.


[00030] In the compounds described herein, W-R1 can be replaced with halogen.

[00031] Halogens are F, Cl, Br, I and At. Preferred halogens are Br, Cl and F.


[00032] Preferred compounds include those having the structure:




-10-



-11-




-12-











Chemical structures of various compounds, including triazine derivatives, are shown. The structures include:



- Triazine derivatives with various substituents, including phenyl, hydroxyphenyl, and triazole groups.
- Compounds with long alkyl chains (e.g., heptyl) and amide linkages.
- Compounds with ether linkages and amide groups.
- Compounds with carboxylic acid and ester functional groups.
- Compounds with triazole and tetrazole rings.



-14-



-15-











-17-




-18-




,




,




,




,




,



,











.




,


-19-




-20-




-21-




-22-




[00033] Preferred compounds include those having the structure:



-23-



[00034] A most preferred compound has the structure:



[00035] The invention also provides a method of treating a condition selected from the group consisting of obesity and pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a prostaglandin transporter inhibitor in an amount effective to treat obesity and/or pulmonary arterial hypertension. PGT inhibitors include those described herein as well as, for example, in Chi et al., 2005; WO 2007/136638; US 2012/0238577.

[00036] The invention further provides a pharmaceutical composition for treating obesity and/or pulmonary arterial hypertension comprising a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier.

[00037] The invention also provides a pharmaceutical composition for treating obesity and/or pulmonary arterial hypertension comprising a prostaglandin transporter inhibitor in an

-24-

amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier.

[00038] By “pharmaceutically acceptable” it is meant a material that (i) is compatible with the other ingredients of the composition without rendering the composition unsuitable for its intended purpose, and (ii) is suitable for use with subjects as provided herein without undue adverse side effects (such as toxicity, irritation, and allergic response). Side effects are “undue” when their risk outweighs the benefit provided by the composition. Non-limiting examples of pharmaceutically acceptable carriers include, without limitation, any of the standard pharmaceutical carriers such as phosphate buffered saline solutions, water, emulsions such as oil/water emulsions, microemulsions, and the like.

[00039] The above-described compounds can be formulated without undue experimentation for administration to a mammal, including humans, as appropriate for the particular application. Additionally, proper dosages of the compositions can be determined without undue experimentation using standard dose-response protocols.

[00040] Accordingly, compositions designed for oral, lingual, sublingual, buccal and intrabuccal administration can be made without undue experimentation by means well known in the art, for example with an inert diluent or with an edible carrier. The compositions may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the pharmaceutical compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. Tablets, pills, capsules, troches and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents. Some examples of binders include microcrystalline cellulose, gum tragacanth or gelatin. Examples of excipients include starch or lactose. Some examples of disintegrating agents include alginic acid, cornstarch and the like. Examples of lubricants include magnesium stearate or potassium stearate. An example of a glidant is colloidal silicon dioxide. Some examples of sweetening agents include sucrose, saccharin and the like. Examples of flavoring agents include peppermint, methyl salicylate, orange flavoring and the like.

[00041] The compounds can easily be administered parenterally such as for example, by intravenous, intramuscular, intrathecal or subcutaneous injection. Parenteral administration can be accomplished by incorporating the compounds into a solution or suspension. Such

solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Parenteral formulations may also include antibacterial agents such as for example, benzyl alcohol or methyl parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

[00042] Rectal administration includes administering the compound, in a pharmaceutical composition, into the rectum or large intestine. This can be accomplished using suppositories or enemas. Suppository formulations can easily be made by methods known in the art. For example, suppository formulations can be prepared by heating glycerin to about 120° C., dissolving the composition in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold.

[00043] Transdermal administration includes percutaneous absorption of the composition through the skin. Transdermal formulations include patches (such as the well-known nicotine patch), ointments, creams, gels, salves and the like.

[00044] Topical administration may be preferred for localized application of the compound, for example, for promoting wound healing or for ocular administration (e.g., eye drops).

[00045] The present invention includes nasally administering to the mammal a therapeutically effective amount of the compound, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream powder, or using a nasal tampon or nasal sponge.

[00046] Where the compound is administered peripherally such that it must cross the blood-brain barrier, the compound is preferably formulated in a pharmaceutical composition that enhances the ability of the compound to cross the blood-brain barrier of the mammal. Such formulations are known in the art and include lipophilic compounds to promote absorption. Uptake of non-lipophilic compounds can be enhanced by combination with a lipophilic substance. Lipophilic substances that can enhance delivery of the compound across the nasal mucus include but are not limited to fatty acids (e.g., palmitic acid), gangliosides (e.g., GM-1), phospholipids (e.g., phosphatidylserine), and emulsifiers (e.g., polysorbate 80), bile salts such as sodium deoxycholate, and detergent-like substances

-26-

including, for example, polysorbate 80 such as Tween™, octoxynol such as Triton™ X-100, and sodium tauro-24,25-dihydrofusidate (STDHF).

[00047] In particular embodiments of the invention, the compound is combined with micelles comprised of lipophilic substances. Alternatively, the compound can be combined with liposomes (lipid vesicles) to enhance absorption. The compound can be contained or dissolved within the liposome and/or associated with its surface. Suitable liposomes include phospholipids (e.g., phosphatidylserine) and/or gangliosides (e.g., GM-1). Bile salts and their derivatives and detergent-like substances can also be included in the liposome formulation.

[00048] The invention also provides for the use of any of the compounds of formula (I) for treating obesity and/or pulmonary arterial hypertension in a subject.

[00049] As used herein, a person is considered obese when their body mass index (BMI), as obtained by dividing the person's weight in kilograms by the square of the person's height in meters, exceeds 30 kg/m².

[00050] Preferably, the compound or prostaglandin transporter inhibitor is administered to a subject in an amount that is effective to reverse, in whole or in part, changes in gene expression associated with pulmonary arterial hypertension, in particular changes in gene expression observed in the lung.

[00051] The present invention is illustrated in the following Experimental Details section, which is set forth to aid in the understanding of the invention, and should not be construed to limit in any way the scope of the invention as defined in the claims that follow thereafter.

EXPERIMENTAL DETAILS

A. Preparation of Chemical Compounds


[00052] Compounds were made according to one of 11 generic schemes described in U.S. Patent Application Publication No. US 2012/0238577, the contents of which are herein incorporated by reference. As an example, one of the schemes is reproduced herein below from US 2012/0238577. A specific example with a corresponding experimental description is given. Other compounds made via that same scheme are listed in tabular form beneath the experimental description. Compounds were synthesized at Provid Pharmaceuticals, Inc., North Brunswick NJ.

[00053] *General procedures.* HPLC was performed on Rainin SD-300 or Varian ProStar equipped with a single wavelength UV detector at 214 nm and linear gradients. Analytical HPLC was performed on a Varian C₁₈ column (microsorb 60-8, 4.6 x 250 mm) at a flow rate


of 1 mL/min. Semi-preparative HPLC was performed on a Varian C₁₈ column (microsorb 60-8, 10.0 x 250 mm) at a flow rate of 5 mL/min. Preparative HPLC was routinely performed on a Varian C₁₈ column (microsorb 60-8, 21.4 x 250 mm) at a flow rate of 20 mL/min. The solvent system used on linear gradients was water with 0.075% TFA (solvent A) vs Acetonitrile with 0.075% TFA (solvent B). Silica gel used in flash column chromatography was obtained from Sorbent Technologies (Atlanta, GA). LC-MS spectra were taken on Waters ZQ LC/MS-ESI or APCI.

[00054] *Generic Scheme:*

Scheme 6



Experimental:




[00055] Preparation of aniline **9**: To a solution of methyl 5-amino salicylate (1.0 eq.), in MeOH (10 mL) was added Boc₂O (1.1 eqs.) followed by TEA (1.1 eqs.). The reaction mixture was allowed to stir for 1 hour. Subsequently, imidazole (0.5 eqs.) was added and the reaction mixture stirred for 10 mins at ambient temperature. The reaction mixture was concentrated *in vacuo* and the residue partitioned between CH₂Cl₂ and water. The layers were separated and the aqueous extracted with CH₂Cl₂ (3x). The combined organics were then washed with 0.1 M HCl (1x, aqueous), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was used without further purification.

-28-

[00056] To a solution of the residue (1.0 eq.) in DMF (10 mL) was added K_2CO_3 (1.2 eqs.) followed by BnBr (1.1 eqs.). The reaction mixture was heated to 60 °C and stirred overnight. The reaction mixture was concentrated *in vacuo* and the residue partitioned between CH_2Cl_2 and water. The layers were separated and the aqueous extracted with CH_2Cl_2 (3x). The combined organics were dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was used without further purification.

[00057] The residue was dissolved EtOAc (3 mL) and concentrated HCl (3 mL) was added. The reaction mixture was stirred for 1 hour at ambient temperature before the reaction mixture was concentrated *in vacuo*. The residue was used without further purification.



[00058] To a solution of cyanuric chloride (1.14 eqs.) and ^tbutyl 4-aminobenzoate (1.0 eq.) in THF (81 mL) was added ⁱPr₂NEt (1.1 eqs.). The reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (3x), and the combined organics were dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was used without further purification.

[00059] To a solution of the residue (1.0 eq.) and aniline **9** (1.1 eqs.) in THF (52 mL) was added ⁱPr₂NEt (3.0 eqs.). The reaction mixture was warmed to 50 °C and stirred overnight. The reaction mixture was cooled to ambient temperature and partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (3x), and the combined organics were dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The residue was used without further purification.

[00060] To a solution of the residue (1.0 eq.) and amine **1** (1.2 eqs.) in THF (1.5 mL) was added ⁱPr₂NEt (3.0 eqs.). The reaction mixture was warmed to 65 °C and stirred overnight. The reaction mixture was concentrated *in vacuo* and the residue was purified *via* column chromatography over silica gel (2:1/hexanes:EtOAc → 98:2/ CH_2Cl_2 :MeOH). The obtained residue (0.116 g, 78 % yield over 3 steps) was used without further purification.

-29-


[00061] The residue (1.0 eq.) was dissolved in TFA (1.0 mL) and DMS (1.0 mL). The reaction mixture was warmed to 50 °C and stirred overnight. The reaction mixture was concentrated *in vacuo* and the residue used without further purification.

[00062] To a mixture of the residue (1.0 eq.), 4-fluorobenzylamine (1.1 eqs.), EDAC·HCl (1.2 eqs.) and anhydrous HOBt (1.2 eqs.) was added DMF (1 mL). Subsequently, *i*-Pr₂NEt (3.0 eqs.) was added to the reaction mixture and the resulting solution stirred overnight. The reaction mixture was then concentrated *in vacuo* and the residue purified *via* reverse phase HPLC to yield triazine **8iii** (25.0 mg, 18% yield over 2 steps).

[00063] A heterogeneous mixture of triazine **8iii** (1.0 eq.) and LiOH (30 eq.) in THF (0.3 mL), MeOH (0.3 mL) and H₂O (0.3 mL) was stirred at ambient temperature overnight. The reaction mixture was then concentrated *in vacuo* and the residue purified *via* reverse phase HPLC to yield triazine **10a** (13.0 mg, 59% yield):MS (ESI): *m/z* = 725 (M+H)⁺; analytical HPLC (10-90% MeCN in H₂O, 20 mins, flow rate = 1.0 mL/min.) *R*_t = 14.91 mins (>96% pure).

[00064] The following compounds were or could be made by the procedure described for triazine **10a**:

-30-



Compound	W	X3	X4	C	R3	R4	R6	R7	(M+H) ⁺
10b	NH	OH	H	0	P	H	NH	CO ₂ H(CH ₂) ₆ -	701
10c	NH	OH	H	0	P	H	NH		707
10d	NH	OH	H	0	P	H	NH		707
10e	NH	OH	H	0	P	H	NH		707
10f	NH	CO ₂ H	H	1	P	H	NH	Bn-	705
10g	NH	CH ₂ CO ₂ H	H	0	P	H	NH	Bn-	705
10h	NH	CO ₂ H	H	0	P	H	NH		709

B. Inhibitory Properties of Compounds

[00065] Inhibitory properties of the compounds were described in U.S. Patent Application Publication No. US 2012/0238577. The results are reproduced herein below from US 2012/0238577.

[00066] MDCK cells stably transfected with rat PGT (Endo et al., 2002) were seeded at 15-20% confluence on 24-well plates. The day on which the cells were seeded was considered day 1. PGE₂ uptake experiments were conducted on day 4. All of the PGE₂ uptake experiments were conducted at room temperature. On day 4, cells were washed twice with Waymouth buffer (135 mM NaCl, 13 mM H-Hepes, 13 mM Na-Hepes, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 0.8 mM MgSO₄, 5 mM KCl, and 28 mM D-glucose). Then 200 μL of Waymouth buffer containing [³H]PGE₂ (purchased from Perkin Elmer) was added to each well. At the designed time, the uptake of [³H]PGE₂ was stopped by aspiration of uptake

-31-

buffer; this was followed by immediate washing twice with 500 μ L of chilled Waymouth buffer. Cells were then lysed with 100 μ L lysis buffer containing 0.25% SDS and 0.05 N NaOH. 1.5 mL of scintillation solution was added to each well, and intracellular [3 H]PGE₂ was counted by MicroBeta Counter.






[00067] For preliminary testing of the compounds, 20 μ L of Waymouth buffer containing the compound was added to each well; this was immediately followed by the addition of 180 μ L of Waymouth buffer containing [3 H]PGE₂. In each well, the total volume of uptake medium was 200 μ L. Organic compounds were first dissolved in EtOH and then diluted in Waymouth buffer. The percent inhibition of [3 H]PGE₂ uptake by compounds was calculated as $[(\text{uptake}_{\text{vehicle}} - \text{uptake}_{\text{inhibitor}}) \div (\text{uptake}_{\text{vehicle}})] \times 100$.

[00068] To determine IC₅₀ of each compound, 20 μ L of Waymouth buffer containing various concentrations of the compound was added to each well; this was immediately followed by the addition of 180 μ L of Waymouth buffer containing [3 H]PGE₂. IC₅₀ was calculated by fitting an equation of $y = m1 - m1 \cdot (m0 / (m2 + m0))$.

[00069] Results for the compounds are presented in Table 1, Inhibitory Activities of PGT Inhibitors. Abbreviations: Bn = benzyl (-CH₂Ph), Bz = benzoyl (-(C=O)Ph), Me = methyl (-CH₃), Ph = phenyl.

Table 1. Inhibitory Activities of PGT Inhibitors

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
T26A			378		72.65				
1		543.62			9.6			8.5	
2		619.71			1.6			6.5	
3		563.05			0.4			1.7	
4		529.59	4850		7.0	32.4		67.6	81.5






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
5		571.67			6.6			9.6	
6		587.67			3.6			11.7	
7		689.80			4.8			22.5	
8		843.81	223.8		52.3				
9		481.55			1.3			18.8	

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
10		497.55			1.4			15.0	
11		599.68			11.4			29.9	
12		568.05			2.8			4.7	
13		687.62			19.2			19.3	
14		700.66			10.6			35.9	

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
15		714.69			15.0			16.6	
16		742.74	9770		11.8			44.8	
17		701.65	6570		22.0			55.6	
18		774.74			21.1			48.9	
19		832.82			41.3			75.0	






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
20		686.63			9.6			14.4	
21		730.69			15.7			68.2	
22		776.76	42.7		62.4			88.1	95.5
23		673.64			14.4			38.4	
24		728.71			1.7			9.2	
25		658.62			12.9			27.7	






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
26		673.64			2.6			35.2	
27		649.66			28.2			53.8	
28		659.61			2.4			56.5	
29		758.62				15.9			49.6
30		661.6				26.1			78.25

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
31		722.51				12.2			69.2
32		673.64				29.0			71.0
33		758.62				13.2			54.6
34		661.6				25.8			81
35		679.59				20.4			75.6

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
36		722.51				30.3			81.1
37		673.64				32.4			79.0
38		679.66				22.8			63.0
39		649.64				42.9			86.2
40		719.71				16.3			46.9

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
41		581.54				0.3			6.6
42		658.62				22.8			57.6
43		828.83	1300			34.8			84.1
44		770.79	760			65.0			77.5
45		653.52				5.0			12.9

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
46		722.69				4.1			32.4
47		846.8				22.6			76.5
48		700.78				14.2			62.8
49		568.5				1.7			12.5
50		550.53				9.3			15.1

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
51		440.45				17.4			29.8
52		422.48				0.1			1.8
53		667.63	4040			65.2		83.4	86.4
54		695.65				33.7			52.2
55		492.49				12.7			26.1

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
56		678.06				38.0			80.5
57		571.63	5570			27.4		29.5	56.6
58		557.6				16.25		41.0	52.5
59		599.56	2460			36.8			75.8
60		699.67				7.2			34.5






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
61		685.65				7.5			46.1
62		611.61				20.4			50.1
63		625.64				11.0			44.1
64		800.78	115		15.5	71.6		77.2	90.2
65		794.82	1380		18.4	66.4		84.0	90.0






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
66		804.81			10.9			64.4	
67		891.77			13.4			76.1	
68		790.78			15.0			70.8	
69		777.74	890		24.9			83.2	
70		891.77	1050		21.2			84.0	






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
71		891.77			16.7			78.4	
72		711.61				19.7		66.1	75.3
73		834.79					38.9	75.3	
74		834.79			45.0		56.9	82.0	
75		667.63				8.4		10.1	12.5






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
76		769.81			13.5		39.9	70.5	
77		712.63			1.8		4.3	23.2	
78		776.76			15.5		24.5	83.2	
79		706.75			5.4		29.2	54.9	
80		706.75			0.7		21.8	57.2	






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
81		806.78			0.4		16.2	80.1	
82		844.76			2.1		5.0	47.6	
83		777.74	609		4.1		10.4	42.0	
84		583.56				5.7		13.7	37.1
85		597.58				7.6		12.2	49.6

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
86		806.78	870	50.0	70.7		81.4	86.4	
87		826.82	710	55.1	71.8		83.5	90.6	
88		852.85	820	61.8	67.6		82.6	88.2	
89		811.2			33.8		76.5	86.0	
90		806.78			23.4		60.6	72.7	






Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
91		852.85	620	60.8	72.1		84.0	88.0	
92		815.79			33.7		71.3	80.6	
93		806.78			24.6		43.3	51.1	
94		826.82					66.7	76.1	
95		668.62				1.9		23.4	50.4

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
96		611.61				8.6		23.9	51.9
97		625.64				13.1		19.4	30.8
98		767.15			6.7		24.9	75.1	
99		794.75	23.7	81.3	61.8		77.1	89.4	
100		845.65		41.1	56.4		57.6	86.0	





Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 0.5 μM	Inh (% of Ctl) 1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
101		844.76		47.4	54.0		71.0	91.4	
102		790.78			41.9		65.7	88.0	
103		762.73			38.3		62.2	83.7	
104		845.65		46.6	61.6		87.8	91.6	
105		794.75	47.5	67.9	64.6		81	92.45	

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
106		811.2		68.4	64.8		68.8	93.1	
107		790.78		65.2	56.3		80.7	91.3	
108		845.65		70.3	60.8		78.3	76.6	
109		855.65		49.5	55.6		59.8	85.1	
110		794.75	31.3	69.6	60.6		78.3	93.6	

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
111		790.78		52.2	59.1		81.5	93.2	
112		706.75			17.5		32.2	49.4	
113		844.76		36.8	49.2		84.1	92.4	
114		834.79		41.0	61.4				
115		782.81		54.4	76.8				

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
116		760.76		36.4	59.4				
117		832.82		8.1	36.7				
118		732.7	20.9	74.2	90.7				
119		726.74		57.2	81.4				
120		625.64		11.2	29.1				

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
121		704.77		1.0	28.8				
122		832.82		5.8	38.1				
123		790.78		12.0	36.6				
124		790.78	34	68.8	85.4				
125		704.77		3.2	24.3				

Cpd ID	Structure	Mol. Weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 0.5 μ M	Inh (% of Ctl) 1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
126		812.74		24.0	56.3	70.0			
127		812.74		17.0	52.3	70.2			
128		812.74		36.6	71.8	82.2			
129		812.74		8.9	45.1	65.6			

Cpd ID	Structure	Mol. weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.01 μM	Inh (% of Ctl) 0.05 μM	Inh (% of Ctl) 0.1 μM	Inh (% of Ctl) 2.5 μM	Inh (% of Ctl) 5 μM	Inh (% of Ctl) 10 μM
130		812.74		41.6	73.2	81.7			
131		812.74		22.3	47.0	74.3			
132		875.77		15.0	22.1	32.4			
133		889.79		4.3	12.6	19.4			
134		800.7		14.0	27.7	46.7			
135		847.71		13.2	28.4	49.6			

Cpd ID	Structure	Mol. weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.01 μ M	Inh (% of Ctl) 0.05 μ M	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
136		750.7	23.9	33.3	64.1	77.9			
137		762.73	36.7	42.0	64.9	75.6			
138		768.76		17.8	22.5	34.5			
139		747.72		16.3	30.7	39.0			
140		670.64		11.5	4.5	10.9			

Cpd ID	Structure	Mol. weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.01 μ M	Inh (% of Ctl) 0.05 μ M	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
141		718.72		12.7	22.0	43.5			
142		932.79		8.4	20.1	39.2			
143 (85% pure)		812.74	16.5	33.7	57.8	69.5			
144		852.78		3.4	5.8	10.8			
145		651.56		7.1	3.1	6.9			

Cpd ID	Structure	Mol. weight	IC ₅₀ (nM)	Inh (% of Ctl) 0.01 μ M	Inh (% of Ctl) 0.05 μ M	Inh (% of Ctl) 0.1 μ M	Inh (% of Ctl) 2.5 μ M	Inh (% of Ctl) 5 μ M	Inh (% of Ctl) 10 μ M
146		724.74	44.8	28.5	59.8	70.4			
147		750.7	31.7	44.5	70.2	79.5			
148		786.7		8.4	12.9	20.7			
149		868.75		3.8	9.1	17.6			
150		708		4.2	14.3	23.9			

C. Treatment of Obesity

Introduction

[00070] Vegiopoulos et al. reported that overexpression of cyclooxygenase 2 (COX2) prevented high fat diet (HFD) induced body weight gain by recruiting brown adipocytes (Vegiopoulos et al., 2010), which could increase energy expenditure in the form of heat release. COX is the enzyme controlling the synthesis of prostaglandins (PGs), such as PGI₂ and PGE₂. Further investigation by the same group revealed that PGI₂ analogue induced the differentiation of white adipose tissue (WAT) toward brown adipose tissue (BAT), serving as a molecular mechanism mediating COX2 triggered recruitment of inducible BAT. The biological level of PGs is regulated by their synthesis and catabolism. One of the critical regulators of PG catabolism is prostaglandin transporter (PGT). Global deletion or systemic inhibition of PGT raises PG levels (Chang et al., 2010; Chi et al., 2011). Thus, it was hypothesized that PGT regulates BAT recruitment and thereby modulates energy homeostasis

Methods and Results

[00071] Wild type (WT) C57BL6/J mice (purchased from Jackson lab) at 5-6 weeks of age were fed with chow diet (CD) (providing calories 28.5%, 13.5% and 58% from protein, fat and carbohydrate) or high fat diet (HFD) (providing calories 20%, 60% and 20% from protein, fat and carbohydrate). CD and HFD were purchased from Purina LabDiet (Framingham, MA), and Research Diets (New Brunswick, NJ), respectively. PGT global knockout (KO) mice were fed with HFD at 5-6 weeks of age. Simultaneously, WT-CD, WT-HFD, and PGTKO-HFD mice were treated with vehicle (0.4% DMSO + 0.4% cremophore) or 0.2 mM Compound 146 from Table 1. To prepare Compound 146 solution, Compound 146 was dissolved in 100% DMSO at a concentration of 50 mM. Two mL of either DMSO or 50 mM Compound 146 were transferred into 500 mL drinking water; 2 mL cremophore were added into the mixture. The mixture was homogenous. Mice were housed individually and fed with CD or HFD, and water (with or without Compound 146) *ad libitum*. Food and water intakes and body weight were recorded every other day.

[00072] Figure 1A shows that HFD feeding resulted in substantial weight gain as compared to CD feeding. Both PGT deletion and inhibition with Compound 146 ("PV" in Figure 1) blunted HFD induced weight gain (Figure 1A), without affecting food or water intake (Figure 1B, 1C).

-64-

[00073] Glucose intolerance is often associated with obesity and HFD causes glucose intolerance. Glucose tolerance tests were conducted of mice as shown in Figure 2. Mice were fasted for 12 hours. Glucose was injected intraperitoneally (20% glucose in saline, 2 g/kg body weight), and plasma glucose levels were measured at various time points by tail cut. Figure 2 shows that HFD indeed induced glucose intolerance, and both PGT deletion and inhibition improved HFD induced glucose intolerance.

D. Treatment of Pulmonary Arterial Hypertension

Introduction

[00074] Studies were designed to test the efficacy of compounds in preventing pathology in a classic rodent model of pulmonary arterial hypertension (PAH). Studies were conducted using Compound 146 from Table 1. Hemodynamic indices of PAH were assessed in the rat monocrotaline (MCT) model. The MCT model of PAH is a routinely used model to evaluate the major pathophysiological features related to PAH and serves as a front-line assay for examining potentially therapeutic compounds (e.g., Li et al., 2013; Paffett et al., 2012). Key pathophysiological variables directly related to mortality and morbidity of PSH were evaluated, including right ventricular systolic pressure (RVSP) and right ventricle to left ventricle plus septum weight (RV/LV+S) ratio.

Materials and Methods

[00075] *Animals.* These studies were conducted at the University of New Mexico (UNM). The study complied with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR Parts 1, 2, and 3) and the *Guide for the Care and Use of Laboratory Animals* (National Research Council, 1996). The protocol was reviewed and approved by the University of New Mexico Institutional Animal Care and Use Committee (IACUC) before the initiation of the study. Sprague-Dawley rats approximately 12 weeks old (300-325 g) from Charles River Laboratories were used in the study.

[00076] *Tolerability.* In the first arm of the project, the tolerability of compounds was assessed with twice daily (b.i.d) injections in the naive rodent. Following one week of acclimatization to the UNM housing environments, rats at this time weighing approximately 200-225 g were randomly assigned to either receive a 50 mg/kg injection b.i.d. of Compound 146 (n = 4) or an equivalent weight-based volume of vehicle (Cremophor-NMP) b.i.d. (n = 4). Rats received test article or saline for a total of 7 consecutive days. Blood draws were

-65-

conducted immediately before the 2nd day of injections, before the 4th day, before the 6th day, and at sacrifice. Body weights were obtained at the same times as the blood draws. On the 7th day, blood from both cohorts was collected via cardiac puncture while under anesthesia. Lungs, heart, liver and kidney were collected and snap frozen in liquid nitrogen for post-mortem bioassays.

[00077] *Administration of Test Compound Prior to Efficacy Testing.* Monocrotaline (MCT) (Sigma-Aldrich) was formulated by standardized procedures, by first dissolving in an acidic solution (HCl), diluting with distilled H₂O, then raising the pH to physiological levels (7.35-7.45) with NaOH. MCT (60 mg/kg) or a volume-matched saline solution was injected intraperitoneally once at the beginning of the study. Body weights were collected on day 0, 5, 7, 11, 14, 18, and 21.

[00078] MCT and saline-injected rats (Day 1) were equally and randomly assigned to receive either vehicle (Cremophor-NMP), low dose Compound 146 or high dose Compound 146 via subcutaneous injections (Days 1-21). Injections were administered subcutaneously at 12 hour intervals throughout the study (actual range was 10-14 h).

[00079] *Efficacy Testing.* After 21 days of twice daily subq injections of either vehicle or two concentrations of Compound 146, rats were anesthetized (1.5-2.5% isoflurane; 2 ml/min O₂), shaved and positioned in dorsal recumbence. Anesthesia was maintained at an appropriate depth, with a target heart rate of ~350 bpm to ensure minimal cardio-depressant effects during collection of RVSP.

[00080] Upon absent deep pain reflex, a thoracotomy was performed to reveal the right ventricle and a fluid-filled catheter was inserted beyond the right ventricular free wall to permit recording of right ventricular hemodynamics (ADI Instruments). A digital trace of 10-30 seconds was obtained from which to derive right ventricular diastolic, mean, and systolic pressures, along with heart rate and related hemodynamic measures. Blood was then drawn via cardiac puncture and centrifuged to obtain EDTA plasma. Hearts were removed and the right ventricle dissected free from the septal wall. Each piece was weighed and reported as RV/LV+S. Tissues (plasma, heart, and lung) were excised and frozen in liquid nitrogen for later biochemical analysis. Additionally, kidneys and liver were snap frozen and stored for subsequent analysis.

[00081] *Dose Preparation and Administration. General:* Compound 146 was stored dry at -20°C. Once formulated, solutions were stored at -20 °C. When necessary, redissolution was

-66-

attained through warming (37 °C) and sonication. The compound dissolves in 15% NMP/10% CremophorEL/PBS pH 7.4. The pH of the final solution of Compound 146 should be about <8; therefore, the PBS is still buffering these solutes.

[00082] CremophorEL was purchased from Acros Organics (Fisher Scientific) Cat # 39728 (250 g). N-methyl pyrrolidinone (NMP) was purchased from Sigma-Aldrich Cat 328634 (100 mL).

[00083] The study was initiated with a more dilute formulation. Within about a week of dosing, it was clear that even Vehicle-treated rats were having dermal tolerability issues with the subcutaneous injections. Thus, solutions were reformulated to reduce the concentration of Cremophor and NMP for each injection, which ultimately worked well. The following steps were taken for the first formulation:

1. A solution of Cremophor EL/PBS (pH 7.4) was made by weighing 130 mg of Cremophor and dilute to 1 mL with PBS to make a 13% Cremophor(w/v) solution. When this was added to the compound NMP solution the final Cremophor solution was ~10%. Necessary volumes were modified proportionally depending on the amount of Compound 146 being formulated. Cremophor solution required sonication and heating to 37°C until homogenous (several minutes).
2. 15 mg of Compound 146 was dissolved in 150 µL of N-methyl pyrrolidinone with sonication to ensure that compound is dissolved (or mixed at proportional level for larger batches).
3. While sonicating, 0.85 mL of the Cremophor/PBS solution was added to the compound/NMP solution. The white precipitate was noted for a few seconds but with continued sonication/heating it readily redissolved.
4. Stock solutions were frozen in aliquots and sonicated/heated for a few minutes prior to loading syringes daily.
5. The final solutions were filtered through 0.2 micron filters for sterilization.

After 11 days and observing a likely Vehicle-related toxicity, solutions were reformulated with a greater proportion of Compound 146 in NMP (proportional to 5 g in 20 ml NMP). This enabled a reduced total volume of single injections from roughly 1 ml to 0.4 ml per rat.

[00084] *Daily Observations.* Animals were examined twice per day (morning and evening) on each day of the study. Examinations focused on (1) identifying dead, weak, or moribund animals, and (2) documenting the onset and progression of any abnormal clinical

-67-

signs, especially dermal lesions. Animals found dead were necropsied as soon as possible; for those subjects RV/LVS weight ratios were obtained, but no other parameters were collected.

[00085] *Statistics.* All data were analyzed by a one-way ANOVA with Newman-Keuls post-hoc multiple comparison test. Probability values less than 0.05 were accepted as significant. Normality of distribution was assumed but for all data sets. All data were analyzed with GraphPad Prism v5.02.

Results

[00086] *Tolerability.* In this abbreviated mock protocol of the efficacy study, several aspects were noted of concern. For one, the rats dosed with the 50 mg/kg dose of Compound 146 formulated in NMP and Cremophor demonstrated a heterogeneous failure to thrive, while Vehicle treated rats grew consistently over the 7 days period. The 2 rats in the Compound 146 group that did not ultimately gain weight over the 7 day period were noted as each having a 1.5-2.0 cm diameter cutaneous lesion on their back, close to injection sites.

[00087] *Mortality and Body Weight Changes.* Body weights were captured more frequently than originally planned due to concerns related to vehicle tolerability. However, when the reformulation allowed for a reduced volume of injection (and thus lower dose of the vehicle), growth curves re-established quickly. Recovery of body weight growth was consistent in a general improvement in behavior.

[00088] Mortality was observed in several groups, including saline/vehicle. The overall trends were consistent with what is expected for MCT pathology. Importantly, in groups receiving any dose of Compound 146, there were no lethalitys. Specific numbers for lethalitys are as follows:

<u>Group</u>	<u>Deaths/Total N</u>
Saline/vehicle	1/5
Saline/146hi	0/5
MCT/vehicle	2/8
MCT/146lo	0/8
MCT/146hi	0/8

where Compound 146 low dose ("146lo") = 15 mg/kg b.i.d., and Compound 146 high dose ("146hi") = 50 mg/kg, b.i.d.

[00089] *Hemodynamics.* Right ventricular pressures were obtained on all surviving rats using an open chest method. As expected, MCT caused a significant increase in RV systolic

-68-

and mean pressures (Figure 3). In rats receiving either dose of Compound 146, MCT induced no significant effect compared to control rats. However, RV pressures for MCT+Vehicle rats were not statistically different from MCT+Compound 146-treated rats, by ANOVA. Using a restricted analysis of MCT-vehicle compared to MCT-Compound 146, there was a significant reduction by one-tailed unpaired Student's t-test ($P=0.046$ and 0.002 for the low and high dose, respectively).

[00090] RV pulse pressure (difference from systolic to diastolic blood pressure) was calculated to reduce potential variability related to positioning of the force transducer or catheter tip, which can cause small variations in the zero value. Similar to RVSP and RVMP, MCT caused a significant increase in Vehicle-treated rats compared to saline controls (Figure 4). Again, in rats receiving either dose of Compound 146, MCT induced no significant effect compared to control rats. For pulse pressure, however, MCT+Vehicle rats were also statistically different from MCT+Compound 146-treated rats, by ANOVA. Lastly, heart rate (HR) was derived from the RV pressure traces in all subjects for the primary purpose of validating that all rats were within a consistent range of anesthesia during the collection of RV pressure data.

[00091] *Heart Weight and Contractility.* As expected, MCT induced significant right ventricular hypertrophy, as assessed by the ratio of right ventricle weight divided by left ventricle plus septum weight (RV/LVS, or the Fulton Index; Figure 5). RV/LVS ratios from saline-treated rats, including those treated with test article, demonstrated mean values of 0.34 to 0.39. MCT-only rats exhibited a mean value of 0.65, which was significantly higher than all saline-treated rats. Both doses of Compound 146 induced a significant inhibition of this RV hypertrophic response, with values of 0.41 and 0.47 in the low and high dose groups, respectively.

[00092] Right ventricular contractility did not display conclusive differences between groups and was mainly used to discriminate MCT-treated rats that might have transitioned from hypertrophic to failing conditions, which would impact RVSP values in a manner counter to the study objectives. In this case, we noted that rat #18, a MCT-vehicle subject, had a RVSP value of 42.4 and a $+dP/dt$ value of 1362, which was well below the mean of 2514 for the group. This subject has been removed from all data analysis, as it was suspected that cardiac failure was ongoing.

-69-

[00093] Lastly, as cardiac dissections were not conducted with full operator blinding, Figure 6 shows the RV and LVS weights were determined for all subjects. Net RV weights were increased by MCT, and the effect blunted by Compound 146. Moreover, there was not an offset in reduced LVS weight. That is, had RV sections been biased, greater LVS weights would be present in the group treated with Compound 146.

[00094] *Lung Weights.* MCT induced a significant increase in total lung weight that was inhibited by Compound 146 at both doses (Figure 6). To better understand the nature of this weight gain, the right lobe was dissected away, the wet weight of this single lobe was captured, the lobe was then dried for 5 days, and re-weighed. Wet weights were consistent with the whole lung wet weight data (Figure 7). Interestingly, dry weights were also consistent with wet weight data, suggesting that MCT treatment led to an increase in structural components of the lung, and that Compound 146 abrogated this remodeling. When the ratio of wet:dry weights were considered, it actually appeared that Compound 146 led to slightly more lung water per mass of tissue in the MCT subjects (but not the saline controls).

Summary

[00095] Overall, it was evident that the test article, Compound 146, had a positive outcome in this commonly-used rodent model of pulmonary arterial hypertension. Most cardiopulmonary outcomes showed a significant amelioration of MCT effects by Compound 146. Four principal outcomes measured suggest a benefit from the test article: RVSP, RV/LVS, lung weight, and mortality.

REFERENCES

Agarwal R, Gomberg-Maitland M. Prognostication in pulmonary arterial hypertension. *Heart Fail Clin.* 2012 Jul;8(3):373-83.

Alm A (1998) Prostaglandin derivatives as ocular hypotensive agents. *Progress in Retinal and Eye Research* 17:291-312.

Bao Y, Pucci ML, Chan BS, Lu R, Ito S and Schuster VL (2002) Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. *American Journal of Physiology* 282:F1103-1110.

Bito LZ and Salvador EV (1976) Effects of anti-inflammatory agents and some other drugs on prostaglandin biotransport. *J.Pharmacol.Exp.Ther.* 198:481-488.

-70-

Blatteis CM and Sehic E (1997) Fever: How may circulating pyrogens signal the brain? *News in Physiological Sciences*. 12:1-9.

Bley KR, Hunter JC, Eglen RM and Smith JA (1998) The role of IP prostanoid receptors in inflammatory pain. *Trends Pharmacol Sci* 19:141-147.

Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP and Versteeg HH (2004) Prostanoids and prostanoid receptors in signal transduction. *Int J Biochem Cell Biol* 36:1187-1205.

Carter R, Mouralidarane A, Ray S, Soeda J, Oben J. Recent advancements in drug treatment of obesity. *Clin Med*. 2012 Oct;12(5):456-60.

Chang, H.Y., Locker, J., Lu, R., and Schuster, V.L. (2010). Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. *Circulation* 121, 529-536.

Chi Y, Khersonsky SM, Chang YT, Schuster VL. Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport. *J Pharmacol Exp Ther*. 2006 Mar;316(3):1346-50. Epub 2005 Nov 3.

Chi, Y., Min, J., Jasmin, J.F., Lisanti, M.P., Chang, Y.T., and Schuster, V.L. (2011). Development of a high-affinity inhibitor of the prostaglandin transporter. *The Journal of Pharmacology and Experimental Therapeutics* 339, 633-641.

Clyman RI, Mauray F, Roman C and Rudolph AM (1978) PGE2 is a more potent vasodilator of the lamb ductus arteriosus than is either PGI2 or 6 keto PGF1alpha. *Prostaglandins* 16:259-264.

Coceani F and Olley PM (1988) The control of cardiovascular shunts in the fetal and perinatal period. *Can J Physiol Pharmacol* 66:1129-1134.

Endo S, Nomura T, Chan BS, Lu R, Pucci ML, Bao Y and Schuster VL (2002) Expression of PGT in MDCK cell monolayers: polarized apical localization and induction of active PG transport. *American Journal of Physiology* 282:F618-F622.

Epstein M (1986) *Prostaglandins and the kidney*. *American journal of medicine*; v. 80, no. 1A, 1986. Technical Publishing, New York, N.Y.

Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth factor. *Endocr Rev* 18: 4-25.

Helliwell RJ, Adams LF and Mitchell MD (2004) Prostaglandin synthases: recent developments and a novel hypothesis. *Prostaglandins Leukotrienes and Essential Fatty Acids* 70:101-113.

Holes-Lewis KA, Malcolm R, O'Neil PM. Pharmacotherapy of obesity: clinical treatments and considerations. *Am J Med Sci*. 2013 Apr;345(4):284-8.

Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW and Meier PJ (1994) Expression cloning of a rat liver Na⁺-independent organic anion transporter. *Proc Natl Acad Sci U S A* 91:133-137.

Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW and Schuster VL (1995) Identification and characterization of a prostaglandin transporter. *Science* 268:866-869.

Li J, Long C, Cui W, Wang H. Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. *J Cardiovasc Pharmacol Ther*. 201318(1):60-9. Epub 2012 Sep 4.

Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, and DuBois RN (2006) Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. *Cancer Res* 66: 6649-56.

Narumiya S, Sugimoto Y and Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. *Physiological Reviews* 79:1193-1226.

Nomura T, Lu R, Pucci ML and Schuster VL (2004) The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. *Mol Pharmacol* 65:973-978.

Paffett ML, Hesterman J, Candelaria G, Lucas S, Anderson T, Irwin D, Hoppin J, Norenberg J, Campen MJ. Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. *PLoS One*. 2012;7(7):e40910, 9 pages, Epub 2012 Jul 17.

Patel R, Aronow WS, Patel L, Gandhi K, Desai H, Kaul D, Sahgal SP. Treatment of pulmonary hypertension. *Med Sci Monit*. 2012 Apr;18(4):RA31-9.

Samad TA, Sapirstein A and Woolf CJ (2002) Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. *Trends Mol Med* 8:390-396.

Santo Domingo L, Scheimann AO. Overview of the epidemiology and management of childhood obesity. *Minerva Pediatr*. 2012 Dec;64(6):607-13.

-72-

Seybold VS, Jia YP, and Abrahams LG. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. *Pain*. 2003 Sep;105(1-2):47-55.

Schuster VL (2002) Prostaglandin Transport. *Prostaglandins and Other Lipid Mediators* 68-69:633-647.

Shao J, Sheng GG, Mifflin RC, Powell DW, and Sheng H (2006) Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. *Cancer Res* 66: 846-55.

Sheng H, Shao J, Washington MK, and DuBois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. *J Biol Chem* 276: 18075-81.

Smith GCS, Coleman RA and McGrath JC (1994) Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus. *Journal of Pharmacology & Experimental Therapeutics* 271:390-396.

Southall MD and Vasko MR (2000) Prostaglandin E(2)-mediated sensitization of rat sensory neurons is not altered by nerve growth factor. *Neurosci Lett* 287: 33-36.

Southall MD and Vasko MR (2001) Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. *J Biol Chem* 276: 16083-91.

Stjernerchantz J (1995) Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. *Advances in Prostaglandin Thromboxane and Leukotriene Research* 23:63-68.

Stjernerchantz J (2004) Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment. *Experimental Eye Research* 78:759-766.

Susanna R, Jr., Chew P and Kitazawa Y (2002) Current status of prostaglandin therapy: latanoprost and unoprostone. *Survey in Ophthalmology* 47 Suppl 1:S97-104.

Sweet DH, Wolff NA and Pritchard JB (1997) Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. *J.Biol.Chem.* 272:30088-30095.

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell* 93: 705-716.

Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, AguilleCJ. and Baulieu EE (1992) Medical termination of early pregnancy with mifepristone (RU 486)

followed by a prostaglandin analogue. Study in 16,369 women. *Acta Obstet.Gynec.Scand.* 71:278-283.

Vanegas H and Schaible HG (2001) Prostaglandins and cyclooxygenases [correction of cyclooxygenases] in the spinal cord. *Prog Neurobiol* 64:327-363.

Vegiopoulos, A., Muller-Decker, K., Strzoda, D., Schmitt, I., Chichelnitskiy, E., Ostertag, A., Berriel Diaz, M., Rozman, J., Hrabe de Angelis, M., Nusing, R.M., *et al.* (2010). Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. *Science* 328, 1158-1161.

Wang JL, Cheng HF, Zhang MZ, McKanna JA and Harris RC (1998) Selective increase of cyclooxygenase-2 expression in a model of renal ablation. *Am.J.Physiol.* 275:F613-F622.

Yao A. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. *J Cardiol.* 2012 Nov;60(5):344-9. Epub 2012 Oct 12.

Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M and Tanabe T (2002) Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. *Circulation* 106:2397-2403.

Young MR (2004) Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. *Angiogenesis* 7: 123-131.

U.S. Patent No. 5,792,851, issued August 11, 1998, Human Prostaglandin Transporter, Schuster et al.


U.S. Patent Application Publication No. US 2012/0238577, published September 20, 2012, Prostaglandin Transporter Inhibitors and Uses Thereof, Schuster et al.

PCT International Patent Application Publication No. WO 2007/136638 A2, published November 29, 2007, Prostaglandin Transporter Inhibitors.

-74-

What is claimed is:



1. A method of treating a condition selected from the group consisting of obesity and pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension, wherein formula (I) is:



wherein


W is O or NR₅;

R₁ is H, -CH₃, -(CH₂)₂OH,



R₃ is -(CH₂)₅CH₃, -(CH₂)₆CO₂H, -(CH₂)₆CO₂CH₃, -(CH₂)_dNHCO-Ph,





-75-



R4 and R5 are independently H or -CH₃;


R6 is O or NR₉;

R7 is H, -CH₃, -C(CH₃)₃, -CH₂OH, -(CH₂)₂OH, -(CH₂)₂O(CH₂)₂OH,
 -(CH₂CH₂O)₃CH₃, -(CH₂CH₂O)₂CH₂CO₂CH₃, -(CH₂)₅CH₃,



-76-


R8 is H, -OH, -CH₂OH, -CO₂H, -CO₂CH₂CH₃, -CO(CH₂)₆CH₃, -OCH₃, -NH₂,





-SO₂NH₂, -CONH-Bn or ;


R9 is H or -CH₃;

R10 is -CH₂NH₂, -CO₂H or -CO₂CH₃;

R11 is -SO₂-Ph, -CH₂-Ph, -CONH-Ph, -COCH₃,



R12 is -CH₃, , , , ,



where X1, X2, X3, X4, X5, X6 and X7 are independently H, halogen, -OH, -CH₃, -CF₃, -OCH₃, -CO₂H, -CO₂CH₃, -CH₂CO₂H, -CH₂CO₂CH₃, phenyl or -O-Bn; and


where a = 0-2; b = 1-6; c = 0-1; d = 4-7; and e = 0-1;

or a pharmaceutically acceptable salt thereof.

2. The method of Claim 1, wherein W is NR5.
3. The method of Claim 1 or 2, wherein R6 is NR9
4. The method of any of Claims 1-3, wherein at least one of R4, R5 and R9 is H.

-77-


5. The method of any of Claims 1-3, wherein all of R4, R5 and R9 are H.
6. The method of any of Claims 1-5, wherein one of X1 and X2 is H, and the other is halogen, -CF₃, -CH₃, -CO₂H, -CO₂CH₃, -OCH₃ or phenyl.
7. The method of any of Claims 1-6, wherein one of X3 and X4 is -OH, and the other is halogen, -CO₂H or -CO₂CH₃.
8. The method of any of Claims 1-7, wherein X7 is H, -CF₃ or -OCH₃.
9. The method of any of Claims 1-8, wherein X1 is located in meta position and X2 is located in para position.
10. The method of any of Claims 1-9, wherein X1 is located in ortho position and X2 is located in para position.
11. The method of any of Claim 1-10, wherein X3 is in meta position and X4 is in para position.
12. The method of any of Claims 1-11, wherein X5 or X6 is in meta position.
13. The method of any of Claims 1-12, wherein X5 or X6 is in para position.
14. The method of Claim 1, wherein the compound has the structure:



-78-


or a pharmaceutically acceptable salt thereof.

15. The method of Claim 1, wherein the compound has the structure:





or a pharmaceutically acceptable salt thereof.

16. The method of Claim 1, wherein the compound has the structure:




or a pharmaceutically acceptable salt thereof.

17. The method of Claim 1, wherein



-79-






where X1, X2, X3, X4, X5 and X6 are independently H, halogen, -OH, -CH₃, -CF₃, -OCH₃, -CO₂H, -CO₂CH₃, -CH₂CO₂H or -CH₂CO₂CH₃; and

where a = 1-2; and b = 1-5;

or a pharmaceutically acceptable salt thereof.

18. The method of Claim 1, wherein



where X1 is H or halogen;

where X4 is H, halogen or -CO₂H; and


where X5 is H, halogen or -OCH₃;

or a pharmaceutically acceptable salt thereof.

19. The method of any of Claims 1-18, where R5 is H.

-80-


20. The method of Claim 1, wherein the compound has the structure:




or a pharmaceutically acceptable salt thereof.

21. The method of any of Claims 1-20, wherein the halogen is Br, Cl or F.


22. The method of Claim 1, wherein the compound has the structure:




-81-




-82-




-83-




-84-




-85-




-86-











-87-




-88-




-89-



-90-




-92-











or a pharmaceutically acceptable salt thereof.

23. The method of Claim 1, wherein the compound has the structure:




-93-




or

-94-




or a pharmaceutically acceptable salt thereof.

24. The method of Claim 1, wherein the compound has the structure:



or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition for treating obesity and/or pulmonary arterial hypertension comprising a compound of formula (I) in an amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier, wherein formula (I) is:




wherein

W is O or NR⁵;

R¹ is H, -CH₃, -(CH₂)₂OH,

-95-




R4 and R5 are independently H or -CH₃;


R6 is O or NR9;

R7 is H, -CH₃, -C(CH₃)₃, -CH₂OH, -(CH₂)₂OH, -(CH₂)₂O(CH₂)₂OH, -(CH₂CH₂O)₃CH₃, -(CH₂CH₂O)₂CH₂CO₂CH₃, -(CH₂)₅CH₃,

-96-





R8 is H, -OH, -CH₂OH, -CO₂H, -CO₂CH₂CH₃, -CO(CH₂)₆CH₃, -OCH₃, -NH₂,




R9 is H or -CH₃;

R10 is -CH₂NH₂, -CO₂H or -CO₂CH₃;

R11 is -SO₂-Ph, -CH₂-Ph, -CONH-Ph, -COCH₃,



-97-



where X₁, X₂, X₃, X₄, X₅, X₆ and X₇ are independently H, halogen, -OH, -CH₃, -CF₃, -OCH₃, -CO₂H, -CO₂CH₃, -CH₂CO₂H, -CH₂CO₂CH₃, phenyl or -O-Bn; and

where a = 0-2; b = 1-6; c = 0-1; d = 4-7; and e = 0-1;

or a pharmaceutically acceptable salt thereof.

26. A method of treating a condition selected from the group consisting of obesity and pulmonary arterial hypertension comprising administering to a subject having obesity and/or pulmonary arterial hypertension a prostaglandin transporter inhibitor in an amount effective to treat obesity and/or pulmonary arterial hypertension.

27. A pharmaceutical composition for treating obesity and/or pulmonary arterial hypertension comprising a prostaglandin transporter inhibitor in an amount effective to treat obesity and/or pulmonary arterial hypertension and a pharmaceutically acceptable carrier.

28. The method of any of Claims 1-24 or 26, or the pharmaceutical composition of Claims 25 or 27, wherein the subject is obese.

29. The method of any of Claims 1-24 or 26, or the pharmaceutical composition of Claims 25 or 27, wherein the subject has pulmonary arterial hypertension.




FIGURE 1A-1C




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/42628

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/53; A61P 3/04, 9/12 (2014.01)

CPC - A61K 31/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 31/53; A61P 3/04, 9/12 (2014.01)

CPC: A61K 31/53 USPC: 514/245

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US Granted, US Applications, EP-A, EP-B, WO, JP, DE-G, DE-A, DE-T, DE-U, GB-A, FR-A); ProQuest; Google Advanced Search; IP.com; KEYWORDS: prostagland* transport* inhibit*, PGT*, COX 2 inhibit*, diseas*, disorder*, prostagland* activit*, pharmaceut* composition*, accept* carrier*, method*, treat*, hypertens*, administer* mammal*, effect* amount*, obes*, obes* subject*

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2011/037610 A1 (SCHUSTER, VL et al.) 31 March 2011; paragraphs [00025]-[00026], [00029], [00039]	1-2, 3/1-2, 14-18, 20, 22-27
Y	US 2004/0204472 A1 (BRIGGS, M et al.) 14 October 2004; paragraphs [0021], [0025], [0030], [0033]-[0035], [0042]-[0043], [0062], [0065], [1353]	1-2, 3/1-2, 14-18, 20, 22-27
A	US 2012/0196881 A1 (NAJARIAN, T et al.) 02 August 2012; entire document	1-2, 3/1-2, 14-18, 20, 22-27

☐ Further documents are listed in the continuation of Box C.


* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 August 2014 (29.08.2014)

Date of mailing of the international search report

10 OCT 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/42628

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-13, 19, 21, 28-29
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.